Evaluation of the antidiabetic effects of green lipped mussel oil and its combination with low molecular weight fucoidan extracted from Undaria pinnatifida.

Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia and insulin resistance, which is closely associated with obesity and inflammation. This highlights the need for safe anti-diabetic supplements that enhance insulin sensitivity, regulate glucose absorption, and suppress inflammation. Combining natural bioactive compounds is gaining recognition as an effective therapeutic approach. Marine bioactive compounds have garnered attention as potential antidiabetic agents. In this study, the in vitro antidiabetic activities of oil extracts obtained by organic solvent extraction (SVC) from Perna canaliculus and low molecular weight (LMW) fucoidan from Undaria pinnatifida, both individually and in combination, were investigated. The focus was on in vitro anti-inflammatory effects (suppression of IL-6 cytokine levels), enhancement of glucose uptake in C2C12 myotube and 3 T3-L1 adipocyte, modulation of lipid accumulation, and inhibition of α-amylase activity. SVC enhanced glucose uptake in both myotube (50.79 %) and adipocyte (40.15 %) cell lines, reduced α-amylase activity (27.62% - 36.51 %), and suppressed IL-6 secretion to near-basal levels (1.77-3.16 %) in LPS-stimulated myotubes. This is the first report to demonstrate that SVC may exert antidiabetic activity. However, LMW fucoidan did not show antidiabetic activity in this study. In comparison to the individual compounds, the combination demonstrated potential antidiabetic effects, including synergistic enhanced glucose uptake (60.22 % - 66.73 %) and decreased IL-6 levels (2.86 % - 2.55 %) in stimulated myotube cells. However, further in vivo validation and studies on sample composition, structure, and their combined molecular mechanisms are needed.